A solicitation of the national institutes of health (NIH) and the centers for disease control and prevention (CDC) for small business innovation research (SBIR) contract proposals

The National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) are soliciting proposals from small business concerns that possess the research and development (R & D) expertise to conduct innovative research that will contribute toward NIH or CDC mission needs and Small Business Innovation Research (SBIR) program objectives.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES (DHHS), THE NATIONAL INSTITUTES OF HEALTH (NIH) AND THE CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) SMALL BUSINESS INNOVATIVE RESEARCH (SBIR) PROGRAM SOLICITATION PHS-2020-1 is anticipated to be made available on or around July 8, 2019, through both FedBizOpps.gov and the NIH Small Business Innovation Research (SBIR)/Small Business Technology Transfer (STTR) funding web page at https://sbir.nih.gov/funding. This solicitation is anticipated to have a closing date of October 23, 2019 for receipt of proposals.

The purposes of the SBIR program are to: (a) stimulate technological innovation; (b) strengthen the role of small business in meeting Federal research/research & development (R/R & D) needs; (c) foster and encourage participation by socially and economically disadvantaged small business concerns and women-owned business concerns; and (d) increase private sector commercialization of innovations derived from Federal R/R & D, thereby increasing competition, productivity and economic growth.

For purposes of the SBIR program, a small business concern is any business concern that, on the date of award, (1) is organized for profit, with a place of business located in the United States, which operates primarily within the United States or which makes a significant contribution to the United States economy through payment of taxes or use of American products, materials or labor; (2) is in the legal form of an individual proprietorship, partnership, limited liability company, corporation, joint venture, association, trust or cooperative, except that where the form is a joint venture, there must be less than 50 percent participation by foreign business entities in the joint venture; (3) more than 50% directly owned and controlled by one or more individuals (who are citizens or permanent resident aliens of the United States), other business concerns (each of which is more than 50% directly owned and controlled by individuals who are citizens or permanent resident aliens of the United States), an Indian tribe, ANC (Alaska Native Corporation) or NHO (Native Hawaiian Organization) (or a wholly owned business entity of such tribe, ANC or NHO), or any combination of these; OR more than 50% owned by multiple venture capital operating companies, hedge funds, private equity firms, or any combination of these. No single venture capital operating company, hedge fund, or private equity firm may own more than 50% of the concern; AND, (4) has, including its affiliates, no more than 500 employees.*

* Note: This size standard is established by law for the SBIR program, regardless of the NAICS Code assigned. See 13 C.F.R. § 121.702.

THE FOLLOWING RESEARCH TOPICS ARE ANTICIPATED TO BE INCLUDED IN SBIR CONTRACT SOLICITATION PHS-2020-1

NATIONAL INSTITUTES OF HEALTH (NIH)

NATIONAL CENTER FOR ADVANCING TRANSLATIONS SCIENCES (NCATS):

- Alternatives to commercially available cell culture insert membranes and manufacturing techniques.

NATIONAL CANCER INSTITUTE (NCI):

- Manufacturing Innovation for the Production of Cell-Based Cancer Immunotherapies.
- Development of Senolytic Agents for Cancer Treatment.
- Combinatory Treatment Utilizing Radiation to Locally Activate Systemically Delivered Therapeutics.
- Sensing Tools to Measure Biological Response to Radiotherapy.
- Quantitative Biomimetic Phantoms for Cancer Imaging.
- Artificial Intelligence-Aided Imaging for Cancer Prevention, Diagnosis, and Monitoring.
- Spatial Sequencing Technologies with Single Cell Resolution for Cancer Research.
- Subcellular Microscopy and -Omics in Cancer Cell Biology.
- Intra-Tumor Sensing Technologies for Tumor Pharmacotyping.
- Software for Patient Navigation Through the Cancer Care Continuum.
- Cloud-Based Software for the Cancer Research Data Commons.
- Tools and Technologies for Visualizing Multi-Scale Data.
- Software for Automated Analysis of Images for Improved Cancer Health.
- Cancer Clinical Trials Recruitment and Retention Tools for Participant Engagement.
- De-Identification Software Tools for Cancer Imaging Research.
- Software Enabling Data Integration from Wearable Sensors for Cancer Patients.

NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (NHLBI):

- Transcatheter trileaflet tricuspid suture repair system.
- MRI myocardial biopsy system.

NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM (NIAAA):

- Alcohol Biosensor Development for Continuous Alcohol Consumption Monitoring.
- Data Science Tools for Accelerating Alcohol Research.

NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID):

- Co-delivery and Formulation of Adjuvants for HIV Vaccine Development.
- Particle-based Co-delivery of HIV immunogens as Next-generation HIV Vaccines.
- Sequence-based Assays to Quantify the Replication-Competent HIV Reservoir.
- Small Molecule Targeting of HIV RNA.
- Adjuvant Discovery for Vaccines against Infectious or Immune-mediated Diseases.
- Adjuvant Development for Vaccines against Infectious or Immune-mediated Diseases.
- Production of Adjuvants.
- Reagents for Immunologic Analysis of Non-mammalian and Underrepresented Mammalian Models.
- Antiviral drugs to cure chronic hepatitis B virus infection.
- Broad spectrum antibody against human enteroviruses.
- Development of rapid fungal diagnostics for select endemic dimorphic fungi.

CENTER FOR DISEASE CONTROL AND PREVENTION (CDC)

NATIONAL CENTER FOR CHRONIC DISEASE AND HEALTH PROMOTION (NCCDPHP):

- Objective Measurement of Opioid Withdrawal in Newborns

NATIONAL CENTER FOR EMERGING ZOONOTIC AND INFECTIOUS DISEASE (NCEZID):

- Assay to Detect and Quantify E. Coli O157 in Water Samples.
- Device Development for Microbial Surface Sampling Field Extraction and Collection.
- Diagnostic Testing Platform to Assess Antibiotic Communities of Cystic Fibrosis Patients.

NATIONAL CENTER FOR ENVIRONMENTAL HEALTH (NCEH):

- Web-Based Platform for Flooding Vulnerability and HealthCare Access.

NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES (NCIRD):

- Accelerating Time to Detection of Legionella in Environmental Samples.

NOTE - SBIR / STTR GRANT OPPORTUNITIES

SBIR and STTR grant opportunities are also available for investigator-initiated ideas. Companies are encouraged to review omnibus SBIR/STTR grant solicitations of the National Institutes of Health, Centers for Disease Control and Prevention and Food and Drug Administration posted on the NIH SBIR/STTR funding web page located at https://sbir.nih.gov/funding#omni-sbir. Standard due dates for SBIR/STTR grant applications are September 6, 2019, January 6, 2020, and April 6, 2020. To understand better the differences between grants and contracts, see https://sbir.nih.gov/apply .

For general information regarding the NIH/CDC SBIR Program, please refer to:

Office of Extramural Research,
National Institutes of Health
Phone 301-435-2688
sbir@od.nih.gov

.